TrialBlood2007

MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.

Tri K Nguyen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.